Bionoid Pharma Inc
AI Maverick Intel, Inc., an AI company, focuses on acquiring and enhancing businesses through its proprietary AI Maverick platform. Its technology streamlines the customer acquisition process by automating two way communication and data-driven engagement with its clients ideal audience segments across healthcare, biotech, and other sectors. The company was formerly known as Bionoid Pharma Inc. an… Read more
Bionoid Pharma Inc (BINP) - Total Assets
Latest total assets as of June 2025: $4.08 Million USD
Based on the latest financial reports, Bionoid Pharma Inc (BINP) holds total assets worth $4.08 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bionoid Pharma Inc - Total Assets Trend (2006–2023)
This chart illustrates how Bionoid Pharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bionoid Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Bionoid Pharma Inc's total assets of $4.08 Million consist of 73.7% current assets and 26.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $15.19K | 21.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2023)
This chart illustrates how Bionoid Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bionoid Pharma Inc's current assets represent 73.7% of total assets in 2023, an increase from 3.5% in 2006.
- Cash Position: Cash and equivalents constituted 3.8% of total assets in 2023, up from 2.4% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, a decrease from 87.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 21.4% of total assets.
Bionoid Pharma Inc Competitors by Total Assets
Key competitors of Bionoid Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Bionoid Pharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Bionoid Pharma Inc generates 0.53x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Bionoid Pharma Inc generates $ 16.55 in net profit.
Bionoid Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.38 | 0.47 | 0.06 |
| Quick Ratio | 0.38 | 0.47 | 0.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-99.38K | $ -82.37K | $ -2.00 Million |
Bionoid Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Bionoid Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -14.8% |
| Total Assets | $70.84K |
| Market Capitalization | $476.50 USD |
Valuation Analysis
Below Book Valuation: The market values Bionoid Pharma Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bionoid Pharma Inc's assets decreased by 14.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bionoid Pharma Inc (2006–2023)
The table below shows the annual total assets of Bionoid Pharma Inc from 2006 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $70.84K | -14.80% |
| 2022-12-31 | $83.15K | -1.40% |
| 2021-12-31 | $84.33K | -31.85% |
| 2020-12-31 | $123.73K | -76.64% |
| 2019-12-31 | $529.62K | +383765.33% |
| 2013-12-31 | $137.97 | -99.95% |
| 2011-12-31 | $301.88K | -77.30% |
| 2010-12-31 | $1.33 Million | +181.81% |
| 2009-12-31 | $471.97K | +18.10% |
| 2008-12-31 | $399.64K | -9.49% |
| 2007-12-31 | $441.55K | -3.81% |
| 2006-12-31 | $459.04K | -- |